OBJECTIVE
To evaluate the effectiveness of a treatment complex including magnetophoresis with the drug «Argensept» and tear therapy in patients with mild to moderate dry eye syndrome.
MATERIAL AND METHODS
The study was conducted on 50 people (100 eyes) diagnosed with mild to moderate dry eye syndrome (H04.1 according to ICD-10). The average age of the patients was 43.3 years. The patients were divided into 2 groups. The first group (main group) — 25 patients (50 eyes) who underwent a treatment complex, including magnetophoresis with the drug «Argensept» and tear replacement therapy. The second group (comparison group) — 25 patients (50 eyes) who underwent only tear replacement therapy. The healthy group consisted of 20 volunteers without pathology of the organ of vision (40 eyes). To assess the effectiveness of the treatment before and after treatment, all patients underwent a standard ophthalmological examination, including checking visual acuity, tonometry, biomicroscopy, ophthalmoscopy, as well as special research methods to determine the level of tear production, stability of the tear film: Schirmer’s test, Norn’s test, determination of the height of the tear meniscus by optical coherence tomography. To assess the intensity of complaints, subjective condition and quality of life before and after treatment, a survey was conducted using the OSDI (Ocular Surface Desease Index) questionnaire.
RESULTS
After the course of treatment, in the group of patients who underwent a treatment complex including magnetophoresis with the drug «Argensept» and tear replacement therapy, all the studied indicators (Schirmer’s test, Norn’s test, lacrimal meniscus height (LMH) and the OSDI (Ocular Surface Desease Index) questionnaire) approached normal values, while in patients who received only tear replacement therapy, the Schirmer’s test indicator was 23.8% lower than in practically healthy volunteers; the Norn’s test indicator was 37.2% lower than the values of healthy volunteers; the height of the lacrimal meniscus (HML) was significantly increased and amounted to 243.2±4.79 μm, but did not reach the values of practically healthy individuals (292±7.8 μm) and the OSDI questionnaire score slightly decreased (to 14.4±0.87 points) and corresponded to the values of mild dry eye syndrome.
CONCLUSION
The use of a therapeutic complex including magnetophoresis with the drug «Argensept» and tear-removal therapy in patients with mild to moderate dry eye syndrome contributes to a significant increase in the level of tear production and stability of the tear film, a significant reduction in complaints, improvement in the subjective state and an increase in the quality of life.
